137 related articles for article (PubMed ID: 3117133)
1. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity.
Chilosi M; Semenzato G; Cetto G; Ambrosetti A; Fiore-Donati L; Perona G; Berton G; Lestani M; Scarpa A; Agostini C
Blood; 1987 Nov; 70(5):1530-5. PubMed ID: 3117133
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk.
Ambrosetti A; Semenzato G; Prior M; Chilosi M; Vinante F; Vincenzi C; Zanotti R; Trentin L; Portuese A; Menestrina F
Br J Haematol; 1989 Oct; 73(2):181-6. PubMed ID: 2818938
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.
Lauria F; Rondelli D; Raspadori D; Zinzani PL; Benfenati D; Pileri S; Sabattini E; Tura S
Leuk Lymphoma; 1992 May; 7(1-2):103-7. PubMed ID: 1472920
[TBL] [Abstract][Full Text] [Related]
4. Detection of a soluble form of the receptor for interleukin 2 in the serum of patients with hairy cell leukaemia.
Chilosi M; Pizzolo G; Semenzato G; Cetto GL
Int J Biol Markers; 1986; 1(2):101-4. PubMed ID: 3123562
[TBL] [Abstract][Full Text] [Related]
5. Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia.
Semenzato G; Trentin L; Zambello R; Agostini C; Bulian P; Siviero F; Ambrosetti A; Vinante F; Prior M; Chilosi M
Leukemia; 1988 Dec; 2(12):788-92. PubMed ID: 3264362
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia.
Trentin L; Zambello R; Agostini C; Ambrosetti A; Chisesi T; Raimondi R; Bulian P; Pizzolo G; Semenzato G
Blood; 1990 Apr; 75(7):1525-30. PubMed ID: 2317560
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia.
Semenzato G; Pizzolo G; Agostini C; Ambrosetti A; Zambello R; Trentin L; Luca M; Masciarelli M; Chilosi M; Vinante F
Blood; 1986 Jul; 68(1):293-6. PubMed ID: 3719101
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
Griffiths SD; Cawley JC
Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells.
Billard C; Sigaux F; Castaigne S; Valensi F; Flandrin G; Degos L; Falcoff E; Aguet M
Blood; 1986 Mar; 67(3):821-6. PubMed ID: 2936410
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.
Steis RG; Marcon L; Clark J; Urba W; Longo DL; Nelson DL; Maluish AE
Blood; 1988 May; 71(5):1304-9. PubMed ID: 3129046
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
Richards JM; Mick R; Latta JM; Daly K; Ratain MJ; Vardiman JW; Golomb HM
Blood; 1990 Nov; 76(10):1941-5. PubMed ID: 1700727
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
Reiter Z; Tomson S; Ozes ON; Taylor MW
Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
[TBL] [Abstract][Full Text] [Related]
13. Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases.
Faltynek CR; Princler GL; Rossio JL; Ruscetti FW; Maluish AE; Abrams PG; Foon KA
Blood; 1986 Apr; 67(4):1077-82. PubMed ID: 2937469
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia.
Bigda J; Mysliwska J; Baran W; Hellmann A; Mysliwski A
Leuk Lymphoma; 1993 Mar; 9(4-5):371-6. PubMed ID: 8348073
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia.
Bigda J; Mysliwska J; Dziadziuszko R; Bigda J; Mysliwski A; Hellmann A
Leuk Lymphoma; 1993 May; 10(1-2):121-5. PubMed ID: 8104069
[TBL] [Abstract][Full Text] [Related]
18. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G
J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
[TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events.
Trentin L; Ambrosetti A; Zambello R; Agostini C; Masciarelli M; Vinante F; Chilosi M; Pizzolo G; Cetto G; Semenzato G
Leuk Res; 1987; 11(9):843-7. PubMed ID: 3499539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
